Methods of assessment of antiepileptic drugs.
Epilepsy is a symptom with protean manifestations and as such it is a difficult disease in which to carry out a therapeutic trial. The methods available to research workers for the assessment of new antiepileptic drugs are hampered by the fact that epilepsy is a fluctuant condition. Although it is a chronic disorder open to study using cross-over trials and within-patient comparisons, accurate assessment cannot be easily made at any one point in time. Research workers are therefore automatically placed at a time factor disadvantage and this is especially so for those searching for quick methods of evaluating new compounds. The need for a quick and reliable method of assessing a new antiepileptic drug has long been appreciated. This article will discuss the methods currently available and we will begin by considering the most commonly used method of assessment with particular reference to some of the problems involved in conducting a controlled clinical trial in epilepsy.
D000927:Anticonvulsants / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D004569:Electroencephalography; D005071:Evoked Potentials; D006801:Humans; D010775:Photic Stimulation; D012107:Research Design; D012640:Seizures / Q000503:physiopathology / Q000517:prevention & control
D000927:Anticonvulsants